Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2',5'-dimethoxychalcone compound 2 is a synthetic small molecule chalcone derivative investigated for its dual antiplatelet and antineoplastic activities. It serves as a potent inhibitor of Cyclooxygenase-1 (COX-1), binding directly to the enzyme's active site to suppress the formation of thromboxane B2 and inhibit collagen-induced platelet aggregation. In addition to its antiplatelet effects, the compound has demonstrated antiproliferative activity against human bladder cancer cell lines (such as NTUB1). Its anticancer mechanism involves the induction of G1 phase cell cycle arrest through a COX-1 independent pathway, characterized by the increased expression of the cyclin-dependent kinase inhibitors p21 and p27 and a reduction in reactive oxygen species levels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2',5'-dimethoxychalcone compound 2.